CoChat
Sign Up
Cited by 5RNA Research and SplicingCancer-related molecular mechanisms researchCancer Genomics and Diagnostics

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Subtype-specific alternative splicing events in breast cancer identified by large-scale data analysis

Open access
Deguchi, Yui, Kikutake, Chie, Suyama, Mikita·2024·Scientific Reports
DOI 10.1038/s41598-024-65035-yPMC PMC11187070

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Genome analysis in cancer has focused mainly on elucidating the function and regulatory mechanisms of genes that exhibit differential expression or mutation in cancer samples compared to normal samples. Recently, transcriptome analysis revealed that abnormal splicing events in cancer samples could contribute to cancer pathogenesis. Moreover, splicing variants in cancer reportedly generate diverse cancer antigens. Although abnormal splicing events are expected to be potential targets in cancer immunotherapy, the exploration of such targets and their biological significance in cancer have not been fully understood. In this study, to explore subtype-specific alternative splicing events, we conducted a comprehensive analysis of splicing events for each breast cancer subtype using large-scale splicing data derived from The Cancer Genome Atlas and found subtype-specific alternative splicing patterns. Analyses indicated that genes that produce subtype-specific alternative splicing events are potential novel targets for immunotherapy against breast cancer. The subtype-specific alternative splicing events identified in this study, which were not identified by mutation or differential expression analysis, bring new significance to previously overlooked splicing events.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-024-65035-y

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 46

  1. Stratton, M. R., Campbell, P. J. & Futreal, P. A. The cancer genome. Nature 458(7239), 719–724 (2009). · DOI
  2. Esfahani, M. S. et al. Functional significance of U2AF1 S34F mutations in lung adenocarcinomas. Nat. Commun. https://doi.org/10.1038/s41467-019-13392-y (2019). · DOI
  3. Smith, M. A. et al. U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. Nat. Cell Biol. 21(5), 640–650 (2019). · DOI
  4. Zhao, Y., Cai, W., Hua, Y., Yang, X. & Zhou, J. The biological and clinical consequences of RNA splicing factor U2AF1 mutation in myeloid malignancies. Cancers (Basel) 14(18), 4406 (2022). · DOI
  5. Furney, S. J. et al. SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov. 3(10), 1122–1129 (2013). · DOI
  6. Rossi, D. et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: Association with progression and fludarabine-refractoriness. Blood 118(26), 6904–6908 (2011). · DOI
  7. Kahles, A. et al. Comprehensive analysis of alternative splicing across tumors from 8705 patients. Cancer Cell 34(2), 211-224.e6 (2018). · DOI
  8. Bigot, J. et al. Splicing patterns in SF3B1-mutated uveal melanoma generate shared immunogenic tumor-specific neoepitopes. Cancer Discov. 12(3), 872 (2022). · DOI
  9. Bjørklund, S. S. et al. Widespread alternative exon usage in clinically distinct subtypes of Invasive Ductal Carcinoma. Sci. Rep. https://doi.org/10.1038/s41598-017-05537-0 (2017). · DOI
  10. Wang, Z., Wu, Q., Liu, Y., Li, Q. & Li, J. Self-harm prevalence and associated factors among street children in Mashhad, North East of Iran. Arch. Public Health 79, 139 (2021). · DOI
  11. Riley, R. S., June, C. H., Langer, R. & Mitchell, M. J. Delivery technologies for cancer immunotherapy. Nat. Rev. Drug Discov. 18(3), 175–196 (2019). · DOI
  12. Han, N. & Liu, Z. Targeting alternative splicing in cancer immunotherapy. Front. Cell Dev. Biol. https://doi.org/10.3389/fcell.2023.1232146 (2023). · DOI
  13. Ishida, Y., Agata, Y., Shibahara, K. & Honjo, T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11(11), 3887 (1992). · DOI
  14. Iwai, Y. et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. U. S. A. 99(19), 12293 (2002). · DOI
  15. Pearlman, A. H. et al. Targeting public neoantigens for cancer immunotherapy. Nat. Cancer 2(5), 487 (2021). · DOI
  16. La, V. C. et al. Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975. Cancer Mortal. Eur. 21, 1323–1360 (2010).
  17. Prat, A. et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast 24(Suppl 2), S26-35 (2015). · DOI
  18. Tomczak, K., Czerwińska, P. & Wiznerowicz, M. The Cancer Genome Atlas (TCGA): An immeasurable source of knowledge. Contemp. Oncol. (Pozn.) 19(1A), A68-77 (2015).
  19. Wang, Z., Jensen, M. A. & Zenklusen, J. C. A practical guide to The Cancer Genome Atlas (TCGA). Methods Mol. Biol. 1418, 111–141 (2016). · DOI
  20. Schafer, S. et al. Alternative splicing signatures in RNA-seq Data: Percent spliced in (PSI). Curr. Protoc. Hum. Genet. https://doi.org/10.1002/0471142905.hg1116s87 (2015). · DOI
  21. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal 6(269), 1–1 (2013). · DOI · Paper page
  22. Park, J., Lee, J. O., Lee, M. & Chung, Y. J. AS-CMC: A pan-cancer database of alternative splicing for molecular classification of cancer. Sci. Rep. 12(1), 1–9 (2022). · DOI
  23. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B 57, 289–300 (1995). · DOI · Paper page
  24. Mirdita, M. et al. ColabFold: Making protein folding accessible to all. Nat. Methods 19(6), 679–682 (2022). · DOI · Paper page
  25. Rigsby, R. E. & Parker, A. B. Using the PyMOL application to reinforce visual understanding of protein structure. Biochem. Mol. Biol. Educ. 44(5), 433–437 (2016). · DOI
  26. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Biological crystallography features and development of coot. Acta Crystallogr. D Biol. Crystallogr. 66(Pt 4), 486–501 (2010). · DOI · Paper page
  27. Liu, J. et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 173(2), 400–416 (2018). · DOI · Paper page
  28. Anaya, J. OncoLnc: Linking TCGA survival data to mRNAs, miRNAs, and lncRNAs. PeerJ 2(2), e67 (2016).
  29. Gubin, M. M., Artyomov, M. N., Mardis, E. R. & SchreiberTumor, R. D. Tumor neoantigens: Building a framework for personalized cancer immunotherapy. J. Clin. Invest. 125(9), 3413–3421 (2015). · DOI
  30. Türeci, Ö. et al. Targeting the heterogeneity of cancer with individualized neoepitope vaccines. Clin. Cancer Res. 22(8), 1885–1896 (2016). · DOI
  31. Foulkes, W. D., Smith, I. E. & Reis-Filho, J. S. Triple-negative breast cancer. N. Engl. J. Med. 363(20), 1938–1948 (2010). · DOI
  32. Da Silva, L., Clarke, C. & Lakhani, S. R. Demystifying basal-like breast carcinomas. J. Clin. Pathol. 60(12), 1328 (2007). · DOI
  33. Anders, C., Carey, L. A. & Carey, L. Understanding and treating triple-negative breast cancer. Oncology. 22(11), 1233–1243 (2008).
  34. Picher, A. J. & Blanco, L. Human DNA polymerase lambda is a proficient extender of primer ends paired to 7,8-dihydro-8-oxoguanine. DNA Repair (Amst.) 6(12), 1749–1756 (2007). · DOI
  35. Van Loon, B., Hübscher, U. & Maga, G. Living on the edge: DNA polymerase lambda between genome stability and mutagenesis. Chem. Res. Toxicol. 30(11), 1936–1941 (2017). · DOI
  36. Bache, K. G. et al. The growth-regulatory protein HCRP1/hVps37A is a subunit of mammalian ESCRT-I and mediates receptor down-regulation. Mol. Biol Cell 15(9), 4337–4346 (2004). · DOI
  37. Stuchell, M. D. et al. The human endosomal sorting complex required for transport (ESCRT-I) and its role in HIV-1 budding. J. Biol. Chem. 279(34), 36059–36071 (2004). · DOI
  38. Zivony-Elboum, Y. et al. A founder mutation in Vps37A causes autosomal recessive complex hereditary spastic paraparesis. J. Med. Genet. 49(7), 462–472 (2012). · DOI
  39. Hailstones, D. L. & Gunning, P. W. Characterization of Human Myosin Light Chains 1sa and 3nm: Implications for Isoform Evolution and Function. Mol. Cell Biol. 10(3), 1095–1104 (1990).
  40. Lenzs, S., Lohseo, P., Seidel, U. & Arnoldll, H. H. The alkali light chains of human smooth and nonmuscle myosins are encoded by a single gene. Tissue-specific expression by alternative splicing pathways. J. Biol. Chem. 264(15), 9009–9015 (1989). · DOI
  41. Taylor, D. A., Sack, J. S., Maune, J. F., Beckingham, K. & Quiocho, F. A. Structure of a recombinant calmodulin from Drosophila melanogaster refined at 2.2-A resolution. J. Biol. Chem. 266(32), 21375–21380 (1991). · DOI
  42. Yap, K. L., Ames, J. B., Swindells, M. B. & Ikura, M. Diversity of conformational states and changes within the EF-hand protein superfamily. Proteins 37(3), 499–507 (1999). · DOI
  43. Ikura, M. Calcium binding and conformational response in EF-hand proteins. Trends Biochem. Sci. 21(1), 14–17 (1996). · DOI
  44. Sciarrillo, R. et al. The role of alternative splicing in cancer: From oncogenesis to drug resistance. Drug Resist. Updates 53, 100728 (2020). · DOI
  45. Veuger, M. J. T., Heemskerk, M. H. M., Willy Honders, M., Willemze, R. & Barge, R. M. Y. Functional role of alternatively spliced deoxycytidine kinase in sensitivity to cytarabine of acute myeloid leukemic cells. Blood 99(4), 1373–1380 (2002). · DOI
  46. Jahn, S. C. et al. GSTZ1 expression and chloride concentrations modulate sensitivity of cancer cells to dichloroacetate. Biochim. Biophys. Acta 1860(6), 1202 (2016). · DOI

Metadata

Authors
Deguchi, Y., Kikutake, C., & Suyama, M.
Affiliations
Kyushu University (JP)
Corresponding author
Suyama, Mikita
ORCID
Venue
Scientific Reports
Publisher
Springer Science and Business Media LLC
Published
2024-06-19
Volume
14
Issue
1
Pages
14158-14158
ISSN
2045-2322 (ISSN-L)
DOI
10.1038/s41598-024-65035-y
PMC
PMC11187070
OpenAlex
W4399805464
Cited by
5
References
2
Citations by year
2026: 2 · 2025: 3
FWCI
0.68
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Japan Society for the Promotion of Science (20K15780)
  • Education and Research Center for Mathematical and Data Science, Kyushu University
  • Core Research for Evolutional Science and Technology (JP19gm1310001)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords
breast cancer, alternative splicing, tumor subtypes, splice variants, cancer immunotherapy, immunotherapy targets, gene expression profiling, TCGA, splicing events
MeSH terms
Data Analysis, Breast Neoplasms, Female, Humans, Mutation, Gene Expression Regulation, Neoplastic, Alternative Splicing, Gene Expression Profiling

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review